Free Trial
NASDAQ:PPBT

Purple Biotech (PPBT) Stock Price, News & Analysis

Purple Biotech logo
$2.54 +0.07 (+2.83%)
(As of 11/21/2024 ET)

About Purple Biotech Stock (NASDAQ:PPBT)

Key Stats

Today's Range
$2.42
$2.61
50-Day Range
$2.47
$147.40
52-Week Range
$2.40
$23.20
Volume
25,665 shs
Average Volume
19,247 shs
Market Capitalization
$3.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.00
Consensus Rating
Buy

Company Overview

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

Purple Biotech Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
36th Percentile Overall Score

PPBT MarketRank™: 

Purple Biotech scored higher than 36% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Purple Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Purple Biotech has only been the subject of 1 research reports in the past 90 days.

  • Read more about Purple Biotech's stock forecast and price target.
  • Earnings Growth

    Earnings for Purple Biotech are expected to decrease in the coming year, from ($0.83) to ($1.65) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Purple Biotech is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Purple Biotech is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Purple Biotech has a P/B Ratio of 0.11. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.08% of the float of Purple Biotech has been sold short.
  • Short Interest Ratio / Days to Cover

    Purple Biotech has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Purple Biotech has recently increased by 8.33%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Purple Biotech does not currently pay a dividend.

  • Dividend Growth

    Purple Biotech does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.08% of the float of Purple Biotech has been sold short.
  • Short Interest Ratio / Days to Cover

    Purple Biotech has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Purple Biotech has recently increased by 8.33%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Purple Biotech has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Purple Biotech this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Purple Biotech insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.98% of the stock of Purple Biotech is held by insiders.

  • Percentage Held by Institutions

    Only 9.64% of the stock of Purple Biotech is held by institutions.

  • Read more about Purple Biotech's insider trading history.
Receive PPBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Purple Biotech and its competitors with MarketBeat's FREE daily newsletter.

PPBT Stock News Headlines

Purple Biotech's (PPBT) Buy Rating Reiterated at HC Wainwright
[625,000% Gain] – Are You Ready for the Next Altcoin Boom?
All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.
Purple Biotech reports Q3 EPS (39c) vs ($4.63) last year
See More Headlines

PPBT Stock Analysis - Frequently Asked Questions

Purple Biotech's stock was trading at $147.3980 at the beginning of 2024. Since then, PPBT stock has decreased by 98.3% and is now trading at $2.54.
View the best growth stocks for 2024 here
.

Purple Biotech Ltd (NASDAQ:PPBT) released its quarterly earnings data on Tuesday, November, 21st. The company reported ($4.60) EPS for the quarter, hitting analysts' consensus estimates of ($4.60).

Purple Biotech's stock reverse split on the morning of Tuesday, September 17th 2024. The 1-20 reverse split was announced on Friday, September 13th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of PPBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Purple Biotech investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Broadcom (AVGO), General Electric (GE), Adobe (ADBE) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

Last Earnings
11/21/2023
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PPBT
Previous Symbol
NASDAQ:KTOV
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$33.00
High Stock Price Target
$33.00
Low Stock Price Target
$33.00
Potential Upside/Downside
+1,199.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-19,880,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$22.15 per share

Miscellaneous

Free Float
1,291,000
Market Cap
$3.38 million
Optionable
Optionable
Beta
1.11
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:PPBT) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners